Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Text Size

Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2006 by Sheba Medical Center.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Stanley Medical Research Institute
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00138775
First received: August 28, 2005
Last updated: December 24, 2006
Last verified: October 2006
History of Changes
  Purpose

The goal of the present study is to evaluate the effect of D-serine, added to antipsychotic treatment, on negative and cognitive symptoms in schizophrenia.

The investigators are hypothesizing that D-serine will improve cognitive functioning and negative symptoms.


Condition Intervention Phase
Schizophrenia
Schizoaffective Disorder
 Drug: D-serine
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: D-Serine Adjuvant Pharmacotherapy for the Treatment of Schizophrenia

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
Drug Information available for: Serine
U.S. FDA Resources

Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • SANS - Scale for the Assessment of Negative Symptoms - weeks 0, 8 and 16
  • Measurement and Treatment Research for Cognition in Schizophrenia (MATRICS) battery - visit weeks 0, 8 and 16

Secondary Outcome Measures:
  • Positive and Negative Syndrome Scale of Schizophrenia (PANSS) positive, negative, general and total score - weeks 0, 8 and 16
  • Simpson-Angus Scale (SAS) total score - weeks 0, 8 and 16
  • Clinical Global Impressions (CGI) score - weeks 0, 8 and 16
  • Calgary Depression Scale for Schizophrenia (CDSS) score - weeks 0, 8 and 16
  • Side effect check list
Estimated Enrollment: 200
Study Start Date: October 2004
Estimated Study Completion Date: October 2007
  Eligibility
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) diagnosis of schizophrenia and\or schizoaffective disorder.
  • Age between 18 to 64.
  • PANSS negative symptom score higher than 19.
  • SAS total score lower than 12.
  • CDSS suicidal risk lower than 2

Exclusion Criteria:

  • Epilepsy
  • Meets DSM-IV criteria for mental retardation.
  • Medical condition which confounds presentation or treatment (e.g. uncontrolled diabetes mellitus, history of kidney stones, acute drug toxicity, dementia, delirium, stroke, etc.)
  • Meets DSM-IV criteria for alcohol or drug dependence in last 6 months.
  • Meets DSM-IV criteria for alcohol or drug abuse in last one month.
  • Treatment with clozapine.
  • Current positive pregnancy test or not using acceptable method of birth control.
  • Meets DSM-IV criteria for current anxiety or mood disorders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00138775

Contacts
Contact: Mark Weiser, MD ++972-352-6666575 mweiser@netvision.net.il

Locations
Israel
Ha-Emek Medical Center Not yet recruiting
Afula, Israel
Contact: Ilana Kremer, MD    ++972-46494350    kremer@aviv-pcb.com   
Principal Investigator: Ilana Kremer, MD         
Mazra Mental Health Center Recruiting
Akko, Israel
Contact: David Liba, MD    ++972-49559644    dliba1@netvision.net.il   
Principal Investigator: David Liba, MD         
Abarbanel Mental Health Center Recruiting
Bat Yam, Israel
Contact: Motti Mashiah, MD    ++972-35552604      
Principal Investigator: Motti Mashiah, MD         
Beer-Yaacov Mental Health Center Recruiting
Beer-Yaacov, Israel
Contact: Yehuda Abramovitch, MD    ++972-89258221    byabramovitch@beer-ness.health.gov.il   
Principal Investigator: Yehuda Abramovitch, MD         
Shalvata Mental Health Center Recruiting
Hod Hasharon, Israel
Contact: Yehiel Levkovitch, MD    ++972-97478568    ylev@clalit.org.il   
Principal Investigator: Yehiel Levkovitch, MD         
Kfar Shaul Psychiatric Hospital Recruiting
Jerusalem, Israel
Contact: Alexander Teitelbaum, MD    ++972-26448780    teital@barak-online.net   
Principal Investigator: Alexander Teitelbaum, MD         
The Sarah Herzog Memorial Hospital Recruiting
Jerusalem, Israel
Contact: Uriel Heresco-Levy, MD    ++972-25316906    heresco@md2.huji.ac.il   
Principal Investigator: Uriel Heresco-L         
Nes-Ziona Mental Health Center Recruiting
Nes Ziona, Israel
Contact: Daniela Amital, MD    ++972-50-8647067      
Principal Investigator: Daniela Amital, MD         
Lev Hasharon Mental Health Center Recruiting
Pardesiyya, Israel
Contact: Dimitri Rudinski, MD    ++972-98981210    drudinski@lev-hasaron.co.il   
Principal Investigator: Dimitri Rudinski, MD         
Geha Mental Health Center Recruiting
Petah Tiqwa, Israel
Contact: Shai Konas, MD    ++972-50-7215226    konass@clalit.org.il   
Principal Investigator: Shai Konas, MD         
Sheba Medical Center Recruiting
Ramat-Gan, Israel
Contact: Mark Weiser, MD    ++972-52-6666576    mweiser@netvision.net.il   
Principal Investigator: Mark Weiser, MD         
Shaar Menashe Mental Health Center Not yet recruiting
Shaar Menashe, Israel
Contact: Shmuel Hirschmann, MD       hirscmann@shaar-menashe.org.il   
Principal Investigator: Shmuel Hirschman, MD         
Jaffa Mental Health Center Recruiting
Tel Aviv, Israel
Contact: Yosef Zimerman, MD    ++972-35151117    zimermanj@yahoo.com   
Principal Investigator: Yosef Zimerman, MD         
Maccabi Mental Health Center Not yet recruiting
Tel Aviv, Israel
Contact: Yerechmiel Barber, MD    ++972-35122196    ybarber@hotmail.co.il   
Principal Investigator: Yerechmiel Barber, MD         
Sponsors and Collaborators
Sheba Medical Center
Stanley Medical Research Institute
Investigators
Principal Investigator: Mark Weiser, MD Sheba Medical Center
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00138775     History of Changes
Other Study ID Numbers: SHEBA-03-3093-MW-CTIL
Study First Received: August 28, 2005
Last Updated: December 24, 2006

Keywords provided by Sheba Medical Center:
D-serine
Negative symptoms
Cognition
Schizophrenia
Amino acid

Additional relevant MeSH terms:
Schizophrenia
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 25, 2017